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Abstract: In this study, we report how the cholera toxin (CT) A subunit (CTA), the enzyme moiety
responsible for signaling alteration in host cells, enters the exosomal pathway, secretes extracellularly,
transmits itself to a cell population. The first evidence for long-term transmission of CT’s toxic
effect via extracellular vesicles was obtained in Chinese hamster ovary (CHO) cells. To follow
the CT intracellular route towards exosome secretion, we used a novel strategy for generating
metabolically-labeled fluorescent exosomes that can be counted by flow cytometry assay (FACS) and
characterized. Our results clearly show the association of CT with exosomes, together with the heat
shock protein 90 (HSP90) and Protein Disulfide Isomerase (PDI) molecules, proteins required for
translocation of CTA across the ER membrane into the cytoplasm. Confocal microscopy showed
direct internalization of CT containing fluorescent exo into CHO cells coupled with morphological
changes in the recipient cells that are characteristic of CT action. Moreover, Me665 cells treated
with CT-containing exosomes showed an increase in Adenosine 3’,5’-Cyclic Monophosphate (cAMP)
level, reaching levels comparable to those seen in cells exposed directly to CT. Our results prompt
the idea that CT can exploit an exosome-mediated cell communication pathway to extend its
pathophysiological action beyond an initial host cell, into a multitude of cells. This finding could
have implications for cholera disease pathogenesis and epidemiology.
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1. Introduction
In the 21st century, cholera remains an epidemic or endemic disease in many parts of the world.
It is caused by some serogroups of the bacterium Vibrio cholerae which colonize the small intestine and
secrete the Cholera Toxin (CT) protein [1]. CT is made up of two major subunits, A and B [2], similar
to other members of the AB5 family of toxins, and, once secreted by bacteria as a holotoxin, enters host
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cells by hijacking endogenous internalization and intracellular trafficking pathways, culminating in
the induction of toxicity [3]. The A subunit (CTA) represents the enzymatic portion of the enterotoxin,
and is composed of a globular A1 domain (CTA1), which possesses Adenosine 5’-diphosphate
(ADP)-ribosylating activity, and the A2 domain (CTA2), that stabilizes the homo-pentameric B subunits
(CTB) by noncovalent binding.
Internalization of CT depends on interaction of the CTB subunits of the toxin with GM1
gangliosides. GM1 gangliosides are typically concentrated in organized signaling centers such as lipid
rafts and caveolae [4–6]. Localization of the cholera toxin within caveolae has triggered the idea that
these sites may constitute clathrin independent carriers of the toxin. Although there is no evidence
that CT enters cells specifically through the caveolae pathway, experiments have shown that GM1 and
Caveolin-1 (Cav-1) expression levels are selective factors for the caveolae/raft-dependent endocytosis
of cholera toxin [7].
Extracellular secretion gives rise to a variety of vesicles (EV), including those strictly derived from
MVBs and properly defined as exosomes. Exosomes (exo) are vesicles of 30–150 nm diameter that
are secreted by cells into their environment. They are generated by inward budding of endosomal
membranes to form multivesicular bodies (MVBs). Fusion of MVBs with the plasma membrane
typically releases multiple exosomes [8,9]. An increasing number of intracellular molecules has been
reported to enter into exosomes and to be secreted in the extracellular space, suggesting a role for these
vesicles as shuttles that deliver cargo molecules from one cell to another, and whose contents may be
used for monitoring the metabolic state of the cell [10–12].
A few studies have examined the involvement of exo in toxin trafficking. The lethal factor (LF) of
Anthrax toxin, a major Bacillus anthracis virulence factor, is translocated into the lumen of endosomal
intraluminal vesicles (ILVs). It persists in them for days, and can be transmitted to neighboring cells
via exosomes [13]. Trichosanthin (TCS), a plant toxin, is incorporated into intraluminal vesicles of
the MVB, and is then secreted in association with exosomes upon fusion of the MVB with the plasma
membrane [14]. In this paper, we show that that internalized CT molecules are sorted into MVBs,
and are secreted as exosomes by Me665 and CHO cells. Furthermore, we show that CT contained
in exosomes may be transferred to naïve recipient cells, and is able to induce morphological and
functional changes typical of CT intoxication. To follow the transport of CT along the MVB/exosome
route, we take advantage of a new methodology based on the fluorescent labeling of the phospholipid
bilayer of exosomes that enabled us to trace and quantify exosome secretion [15].
2. Results
2.1. Extracellular Vesicles Isolated from CHO and Me665 Cells Upon CT Incubation Contain Cholera Toxin
We previously reported that Cav-1, a structural component of caveolae formation, is highly expressed
in human metastatic melanoma cell lines, and is retrieved in isolated fractions of extracellular vesicles
(EV) [16]. Since caveolae are known locations for CTB binding to GM1 gangliosides, we hypothesized
that Cav-1 and CT might share the endocytic pathway that leads to EV secretion. We first evaluated the
relative levels of GM1 and Cav-1 in Me665 melanoma cells and CHO cells. Figure 1A shows that both cell
types expressed these molecules, with higher levels in Me665 cells.
To determine whether CT was secreted in EVs, culture supernatants from CT treated Me665 and
CHO cells (2 × 107 cells for both cell lines) were subjected to differential centrifugation to isolate EVs,
and vesicle pellets were analyzed by western blot for CT presence. Both CTA and CTB subunits were
present in EV pellets from both cell types, and were slightly more abundant in Me665 cells (Figure 1B).
To determine if CT carried by EVs was capable of inducing morphological changes in cells that
had not been directly exposed to CT, we used a well-established CHO cell morphological assay [17].
In this experiment, CHO cells were exposed to 12 nM CT for 2 h, washed, and incubated with fresh
medium (without CT) for 24 h at 37 ◦C. After removal of the conditioned medium, fresh medium
was added (twice), each time for an additional 24 h. EVs were purified from each of the conditioned
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media samples (EV-CT 24 h, EV-CT 48 h and EV-CT 72 h), and as a control, EVs were purified from
replicate CHO cells treated in an identical manner, but without CT-exposure. To determine if the CT
carried by EVs was capable of inducing biological effects in cells that had not been directly exposed
to CT, we used a well-established morphological assay based on CHO cell morphology [17]. Freshly
trypsinized CHO cells were treated for 6 h with 5 µg of EVs from the CT-exposed cells, or with 5 µg
of EVs from control cells. As a positive control, replicates cells were directly exposed to 12 nM CT.
Under normal conditions, most untreated cells remain round (Figure 1C) (even after overnight culture,
not shown). In contrast, when directly exposed to 12 nM CT, the majority of cells became bipolar
and elongated. In the case of cells exposed to EVs derived from CT treated cells, 60–80% became
bipolar and elongated, comparable to cells exposed directly to 12 nM CT (Figure 1C). Notably, EVs
secreted after 48 or 72 h from cells challenged with CT were also able to induce a morphological change,
indicating that functionally active CT is present in the EVs.
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CTB. Actin is shown for normalization; (B) EVs collected from supernatants of CHO and Me665
cells treated with CT were run on a SDS-PAGE gel in reducing conditions Western blot analysis with
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10) analysis of CHO cells upon addition of extracellular vesicles from control or CT treated
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2.2. Quantification and Characterization of Fluorescent Exosomes Containing CT Demonstrate the CTA
Subunit Inclusion
To better define the role of exosomes as a carrier of CT, we applied a method we have developed
based on the production of metabolically labeled fluorescent exo (F-exo), by using the fatty acid analogue
BODIPYTM FL C16 (4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene-3-hexadecanoic Acid) [15].
Upon incubation with cells, BODIPY C16 enters the cellular lipid pathway and is transformed mostly
into phospholipids that will become part of the F-exo lipid bilayer. Accordingly, we labeled Me665
cells for 5 h with BODIPY C16, followed (or not) by the addition of 12 nM CT for 2 h, and incubated
for additional 24 h in fresh media. F-exo were purified by differential centrifugation from conditioned
media, and F-exo were analyzed by FACS. As shown in Figure 2A, both F-exo and F-exo CT appear as
discrete, countable fluorescent populations, comparable in size and fluorescence intensity.
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Figure 2. Characterization and distribution of F-exo CT purified from Me665 cells on an iodixanol
gradient. (A) FACS analysis of F-exo and F-exo CT deriving from Me665 cells incubated with or without
12 nM CT. To design the F-exo region above instrument background noise only phosphate buffered
saline (PBS) was acquired. Note that no events were registered in this region; (B) Western blot analysis
of F-exo and F-exo CT probed with antibodies against exosome markers Alix, Tumor Susceptibility
Gene (TSG)101, CD63 and CD81; (C) The F-exo CT sample was loaded at the bottom of an iodixanol
discontinuous density gradient and subjected to ultracentrifugation for 18 h. The resulting fractions
(1–12) with increasing density were analyzed for vesicles number by FACS and for the presence of
exosome markers TSG101 and ALIX by Western blotting. The fluorescent peak displays a density
ranging from 1.085 to 1.142. Fractions 1–2, 3–4, 5–6, 7–8, 9–10, 11–12 were pooled, trichloroacetic
acid (TCA) precipitated and analyzed by western blot after running a Sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) in reducing condition for the presence of CTA subunit.
For Western blot, an equal volume of each sample was analyzed.
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Equal numbers of F-exo and F-exo CT were characterized by Western blot analysis for the presence
of typical exo markers (Alix, TSG101, CD63 and CD81). Figure 2B shows that these markers are equally
present in both F-exo and F-exo CT preparations, showing that CT does not alter the protein profile of
the exosomes. To further characterize the F-exo population, we loaded F-exo CT onto a continuous
iodixanol gradient to allow optimal separation of EV subtypes of different buoyant densities, and
the gradient fractions were analyzed for vesicle number by FACS (Figure 2C). F-exo CT separated in
a discrete peak of density range 1.085–1.142 g/mL, as measured by refractometry, in accordance with
the previously reported density of exosomes [8]. Western blot analysis of gradient fractions showed
that the exosomal markers TSG101 and Alix colocalized with the fluorescent peak (fractions 7–8),
further indicating that the F-exo population corresponds to bona fide exosomes. The gradient fractions
were also probed by western blot for the presence of CT with a monoclonal antibody against CTA.
Results show that CTA1 was present in the pooled 7–8 fractions, corresponding to the F-exo fluorescent
peak (Figure 2C). This shows the occurrence of the enzymatic moiety of CT in the exosomes.
2.3. Intracellular Distribution of CT in Me665 Cells
To visualize the intracellular trafficking of CT, we first pulsed Me665 cells with BODIPY C16 for
5 h to metabolically label membrane sub-compartments. Cells were then treated with 12 nM CT for
20 min on ice to allow CT binding to the plasma membrane. The cells were then washed (T0) and
incubated with fresh medium for a further 24 h at 37 ◦C (T24). Following fixation, cells were analyzed
by confocal microscopy. As shown in Figure 3A, at T0, CT clearly labeled only the plasma membrane
and no co-localization with BODIPY C16-labeled internal membrane compartments was observed.
Notably, lipid associated fluorescence was not present at the plasma membrane, further suggesting
that F-exo do not derive from plasma membrane direct budding. At T24, CT staining was diffused in
the cytoplasm, as well as in discrete spots, and co-localized with lipid-based fluorescence, suggesting
the presence of CT in late endosomal/MVB compartments.
To further characterize the subcellular localization of CT, we performed confocal microscopy of
CT-treated cells (T24) using antibodies against BMP, a lipid whose occurrence is specific to the late
endosomal MVB/lysosomal membrane tracking pathway [18], and TSG101, a component of ESCRT
that functions in the early stage of MVBs formation [19,20]. Figure 3B shows that CT co-localized
with both BMP and TSG101 (inset), providing additional proof of the intersection of the CT trafficking
pathway with the exosome biogenesis pathway.
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Figure 3. Intracellular distribution of CT in e665 cells labeled with BODIPY C16. (A) Confocal
icroscopy analysis of Me665cells metabolically labeled with BODIPY C16, treated with 12 nM
CT for 20 min on ice, and then incubated with CT-free medium for 24 h at 37 ◦C. Images were
taken at T0 and T24 h after the removal of CT. BODIPY C16 is represented in green and CT in red;
(B) Cells, immunolabeled for BMP or TSG101 (green) and for CT (red) show colocalization of both
with CT, as evidenced in insets. Bar represents 20 µm. For all images DAPI staining was used for
nuclear localization.
2.4. CTA Active Subunit Is Retrieved in Association HSP90/PDI with Respect to F-exo Biogenesis
With the aim of tracking F-exo CT biogenesis in Me665 cells, we pulsed cells with BODIPY C16
for 5 h to allow metabolic labeling of membrane compartments, including MVB before CT addition,
for a further 2 h. Cells were then chased in fresh media for 1 h, before the media was removed and
fresh media added for time intervals of up to 24 h. Exosome purification was performed on each of the
conditioned media samples, to determine the kinetics of F-exo release into the extracellular medium
(Figure 4A).
From as early as 1 h, cells secrete a discrete population of F-exo that can be FACS counted.
F-exo CT collected at 1 h and successively, after the addition of fresh medium, at 24 h (3 × 107 exo
for each time point), were run on SDS-PAGE and immunoblotted with antibodies against CTA and
CTB subunits. Figure 4B shows that CTA was present in F-exo CT at both time points, and was more
evident at 1 h than at 24 h, presumably because the reservoir of CT in the cells was slowly decreasing
over time. In addition, the blots were probed for the presence of HSP90 and protein disulfide isomerase
(PDI), proteins that are required for protein translocation of the unfolded CTA1 domain from the ER
lumen to the cytosol [21]. Both HSP90 and PDI were present in the F-exo CT samples 1 h and 24 h,
indicating that exo may constitute a membrane translocation system that facilitates the spread of CT
toxicity to other cells, since PDI has the ability to dissociate the active CTA1 from the holotoxin. To see
if the native 21 kDa CTA1 subunit was also present in the exosome vesicles, we loaded F-exo CT onto
an SDS-PAGE gel in non-reducing conditions, prior to western blotting with an anti-CTA antibody.
Figure 4C shows that both the 28 kDa CTA (CTA1 + CTA2) and 21 kDa CTA1 bands are visible. Finally,
to assess the localization of CTA, we exposed F-exo CT to chymotrypsin digestion, with or without
Triton X-100, assuming that the CT molecules enclosed within exo lumen would be protected from
hydrolysis by the vesicle membrane (Figure 4D). Western blot analysis with an anti CTA monoclonal
antibody showed that, in the absence of detergent, chymotrypsin degraded a substantial fraction of
exo-associated CTA. However, complete digestion was observed in the presence of Triton X-100 and
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chymotrypsin. These results show that a portion of the CTA component of the exosomes is present
within the lumen of vesicles.
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assess the activation of de ylate cyclase in Me665 cells, we treated cells with control F-exo, or F-exo
CT for 4 h and measured cAMP levels by using a cAMP assay kit. Replicate cells were directly exposed
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(0.2 ng/mL) or to F-exo CT increased cAMP levels to comparable extents, while control F-exo treatment
did not affect cellular cAMP levels. By using fluorescence calibration beads, we could estimate that
by incubating 285 exo per cell in the experiment in Figure 5C, only 35 exo per cell were taken up by
recipient cells (means of 4 experiments, S.D. = 6.5). These data show that CT carried by exosomes is
biologically active in target cells.
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consensus that 1-based binding of is follo e by retrogra e vesic lar trafficking fro the
plas a membrane through early endosomes, the Trans-Golgi Network, and the en oplasmic reticulum
(ER), before the active CTA1 subunit reaches the cytosol and its final specific substrate [23]. This latter
step appears to require interactions with host cell accessory proteins, such as the chaperone Hsp90
and the protein-folding helper enzyme PDI, which allow membrane translocation of the unfolded
CTA1 domain [4,24,25]. Once in the cytosol, CTA1 recovers the active conformation required for
ADP-ribosylation of its target, the α subunit of the heterotrimeric G protein (Gsα) [26,27] activates
adenylate cyclase, giving rise to increased levels of cellular cyclic AMP (cAMP) [28]. It is well
known that CTB binding and cross-linking of five GM1 molecules serve to promote the function of
lipid rafts in toxin trafficking; in fact, lowering the expression of 1 or cholesterol can prevent
Int. J. Mol. Sci. 2018, 19, 1521 9 of 15
CT endocytosis [29–31]. However, the specific intracellular trafficking pathway of GM1 is not well
understood. Despite the fact that many aspects of the CT-GM1 retrograde trafficking pathway from
PM to ER have been elucidated, when three major pathways of CT entry (i.e., caveolin, clathrin,
or Arf6 dependent) are inhibited, no significant reduction in toxicity is observed, and therefore, one or
more as yet unknown pathways have been hypothesized to contribute [32]. A retracing study of
CT intoxicating retrograde pathways carried out using subsets of GM1 (specified by saturated or
unsaturated fluorescent-labeled ceramide chains) showed that CT bound to saturated GM1, in contrast
to that bound to the unsaturated complex forms, is directed towards late endosome compartments
(including MVBs that contain exosomes) rather than towards the classical Golgi/ER pathway [33].
Accordingly, it has been reported that GM1 gangliosides localize in the membrane of exosomes [34].
Notably, previous studies showed that caveolae and lipid raft associated proteins and lipids can take
part in biogenesis and secretion of cell-derived exosomes [16,35,36].
In this study, we reported for the first time that CT can be propagated via EVs in a biologically
active form, and that CT persists in cells long after treatment with the toxin. Accordingly, EVs collected
from cells up to 72 h after their exposure to CT, still contain biologically active CT. Cells release different
types of EVs, not all of endo/lysosomal origin, such as ectosomes that directly bud from the plasma
membrane [18]. To distinguish among different types of vesicles, we applied a novel methodology
that was developed in our lab [15] for the metabolic labeling of exosomes. BODIPY C16, a fluorescent
phospholipid precursor, is efficiently incorporated into cells, and once metabolized in the ER, takes
the endosomal/MVB route to become an integral part of the exosome membrane. Notably, as shown
in Figure 3A, lipid associated fluorescence seemed completely absent from the plasma membrane,
whereby we could exclude its involvement in fluorescent ectosomes generation.
Fluorescent exo secreted in the extracellular medium can be purified and readily counted. It has
also to be noted that the final purified vesicular pellet contains much less vesicles than those present in
the initial medium. In fact, our labeling technique allowed us to determine that a considerable amount
of fluorescent exosomes remain suspended or associated with different kind of debris and serum
macromolecular components in the supernatant and in the low speed pellets. We show here that CTA
is associated with a discrete population of fluorescent exo that express typical exo markers, indicating
that CT is a bona fide component of exosomes (Figure 2). Furthermore, this methodology allowed
us to highlight intracellular membrane compartments that intersect with the trafficking pathway
of internalized CT (Figure 3A). Specifically, colocalization of CT with MVB-specific markers was
observed in the endolysosomal compartment (Figure 3B). This suggests that exosomes, in addition
of being a means of transport, may represent a kind of CT-repository within the MVBs, allowing CT
to be protected from intracellular degradation, and allowing for long-term activity. Despite the fact
that in vitro uptake of exosomes is a complex mechanism which has not yet been clarified, we also
demonstrate that there is a strict relation between the cellular uptake of CT containing exo and
functional alterations in recipient cells highlighted in CHO cells by the morphological changes and in
Me665 cells by direct increase of cellular cAMP levels. A final consideration is that in a physiological
setting, there may be many other factors that can influence the efficiency of cellular uptake, such as
time of exposure, or more importantly, the vicinity between intoxicated cell secreting exosomes and
recipient cells.
F-exo biogenesis studies allowed us to monitor CT secretion over time, highlighting an early
release of F-exo containing CT (at 1 h). At later times (24 h), CT was still present in F-exo, albeit in lower
amounts, showing that the bulk of CT associated with exo is released soon after toxin internalization.
Interestingly, the host cell chaperone HSP90, an established exosomal marker [37], and protein-helper
enzyme PDI were both clearly present in the exosomes, together with the CT subunits (Figure 4B).
Furthermore, CTA was present in exo both in the active reduced form, CTA1 (21 kDa), or as the inactive
disulfide linked CTA1 and CTA2 (28 kDa) form. Chymotrypsin digestion of F-exo containing CT
revealed that the CTA subunit is distributed both outside and inside of exosome membranes. Based on
our results, an appealing speculation is that CTA associated with exo may derive from two distinct
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intracellular routes: upon cell entry, some CT molecules may follow the long chain saturated GM1
pathway [33], presumably along with Cav-1, leading the CT holotoxin direct to the late endosomal
compartment/MVB before being secreted; on the other hand, CTA1 in exosomes may originate from
the canonical ER retrograde pathway, where, by the action of HSP90 and PDI, CTA1 is translocated to
the cytosol and taken up during exo formation by intraluminal vesicles.
In conclusion, starting from the more general hypothesis which suggests that exosomes are
vehicles that can influence cell homeostasis, we found that CT could exploit the exosome biogenesis
pathway to spread its action from a single cell to an entire cell population. In light of our results,
we may hypothesize that V. cholerae fast dynamic mechanism of intestinal infection relies on the effect of
the cell-to-cell transmission of CT containing exo. In fact, in normal healthy adults, primary symptoms
of cholera disease appear from half a day to five days after ingestion of at least 100 million bacteria,
of which only few thousands survive the harsh acidic conditions of the stomach. Afterwards, only
a small handful of bacteria penetrate the thick mucus wall to reach the V. cholerae natural setting,
the small intestine, where they take hold and release CT [38]. We reason that the rapidity by which
infection propagates among lining intestinal epithelia may be caused by the horizontal transfer of
exosomal payloads that include active CTA subunits. This latter readily interacts with the host cell
mechanisms to pump chloride ions into the small intestine, which can pull up to six liters of water
per day through the intestinal cells through osmosis, eventually creating a thriving environment for
bacteria exponential growth. Thus, our study suggests potentially important roles for exosomes in
cholera pathogenesis, and in the dynamics of this infectious disease, given that these vesicles seem to
preserve and protect the toxin, and facilitate its transfer from cell to cell.
4. Materials and Methods
4.1. Cell Culture
The Human melanoma cell line, Me665/1 (Me665), stabilized from surgical specimen obtained
from metastatic lesions at Istituto Nazionale Tumori (Milan, Italy) and CHO (Chinese hamster ovary,
American Type Culture Collection, Rockville, MD, USA) cell line commercially available, were grown
in Dulbecco’s modified Eagle’s medium (DMEM) (EuroClone, S.p.A. Milan, Italy) supplemented with
10% fetal bovine serum (FBS) (Biological Industries, Kibbutz Beit Haemek, Israel), 5 mM L-glutamine,
penicillin (100 units/mL), and streptomycin (100 µg/mL) (complete media, EuroClone S.p.A. Milan,
Italy) at 37 ◦C in a humidified 5% CO2 atmosphere.
4.2. Isolation of EVs from CHO and Me665 Cell Culture Supernatants
For isolation of EVs, subconfluent monolayers of CHO and Me665 cells in exponential growth
were incubated in DMEM supplemented with 0.3% FBS with or without 12 nM CT, and purified from
culture filtrates of Vibrio Cholerae 569 B, serotype Inaba, as described by [39]. After 2 h of CT treatment,
control and CT treated cells were washed in PBS and further cultured in fresh DMEM medium for
24 h before collection of medium for EVs isolation. EVs were isolated from the culture supernatants of
treated and untreated cells by sequential centrifugations, as previously described [15,40], with some
modifications. Briefly, culture supernatant was centrifuged at 2000× g for 20 min at 4 ◦C to pellet
cells debris. Supernatants were transferred to new tubes and centrifuged in a SW41Ti rotor (Beckman,
Coulter, Milan, Italy) at 10,000× g for 20 min at 4 ◦C, and finally ultracentrifuged at 100,000× g for
3 h. Pellets were washed in PBS and ultracentrifuged at the same speed for 3 h to further remove any
residual CT still present in the exo preparation, since, along with vesicles, some free intact CT is also
recycled to the extracellular milieu, and can be found in the supernatant after ultracentrifugation.
4.3. Morphological Analysis of CHO Cells after CT, EV and EV-CT Treatment
Exponentially growing CHO cells were harvested, transferred to 12-well plates (2× 104 cells/well),
and DMEM supplemented with 0.3% FBS. Cells were incubated with or without 12 nM CT, or with EV
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and EV-CT (prepared as described above). After 6 h incubation, cells were inspected microscopically
to analyze the morphological changes.
4.4. Dot Blot and Western Blot Analysis
Cell pellets were lysed in 20 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 2 mM EDTA
with a Protease Inhibitor Cocktail (Roche Applied Sciences, Mannheim, Germany) for 20 min on ice,
and then centrifuged at 2000× g for 10 min. The pellet was discarded and supernatant was kept for
further analysis. Protein concentration was measured using the BCA assay (Thermo Fisher Scientific,
Waltham, MA, USA). The presence of GM1 ganglioside in cell lysates was assessed by the dot blot assay
using horseradish peroxidase (HRP)-conjugated CTB subunit, and revealed with an ECL detection kit
(PierceTM ECL Western Blotting Substrate, Thermo Fisher Scientific). Cell lysates (40 µg) were boiled
and spotted onto a nitrocellulose membrane blocked using 5% Blotting Grade non-fat dry milk in
a TBS-Tween (TBST) buffer (10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% Tween 20) for 45 min at room
temperature (RT), followed by incubation with HRP-CTB dissolved in TBST buffer (1:400) for 1 h at RT.
The reactivity was detected using an ECL detection kit (Pierce). For Western Blot analysis, exosome
preparations were lysed in Laemmli sample buffer, boiled, and loaded onto 10% or 14% SDS-PAGE
gels under reducing or non-reducing conditions. Proteins were blotted onto a nitrocellulose membrane,
and blocked using 5% Blotting Grade non-fat dry milk in TBS-Tween (TBST) buffer (10 mM Tris-HCl
(pH 8.0), 150 mM NaCl, 0.1% Tween 20) for 1 h at RT followed by incubation with primary antibodies.
The following primary antibodies were used: mouse anti-Cholera Toxin A (Clone 2H9) (Immunology
Consultants Laboratory, Inc., Portland, OR, USA) 1:500 and rabbit polyclonal Anti-Cholera toxin
(Sigma Immuno Chemicals, St. Louis, MO, USA) 1:1000; rabbit anti-Caveolin-1 (N-20) (Santa Cruz
Biotechnology, Dallas, TX, USA) 1:1000; rabbit anti-Protein Disulfide Isomerase Polyclonal Antibody
(Stressgen Biotechnologies Corporation, San Diego, CA, USA) 1:1000; rabbit anti-HSP90 α/β (H-114)
(Santa Cruz Biotechnology) 1:1000 dissolved in TBS-Tween (TBST) buffer for 1 h at RT; mouse anti-Alix
(3A9) (Thermo Scientific) 1:1000, rabbit anti-CD63 (SBI) 1:1000, mouse anti-CD81 1:1000, mouse
anti-TSG101 (GeneTex, Inc., Irvine, CA, USA) 1:1000 dissolved in 0.25% Blotting Grade non-fat dry
milk in TBST overnight at 4 ◦C. After washing with TBST, filters were incubated with appropriate
horseradish peroxidase-conjugated secondary antibodies (Bio-Rad, Hercules, CA, USA) for 1 h at RT,
and immunoreactivity was revealed by using an ECL detection kit (Pierce).
4.5. Generation and Quantification of F-exo
F-exo were purified and quantified as previously described [15]. Briefly, melanoma cells Me665
(8 × 105) were incubated with 7 µM BODIPY FL C16 (4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-
indacene-3-hexadecanoic acid) (BODIPY C16) (Life Technologies, Carlsbad, CA, USA) for 5 h at 37 ◦C
in DMEM supplemented with 0.3% FBS. Excess probe was removed by washing cells twice with PBS.
Subsequently, cells were incubated with or without 12 nM CT in DMEM supplemented with 0.3%
FBS for 2 h at 37 ◦C, and washed twice with PBS to remove excess CT and further incubated for
different times in complete media. Conditioned medium was centrifuged at 2000× g for 20 min to
remove cells and cell debris. The pellet was discarded and the supernatant centrifuged at 10,000× g
(10 K) to remove microvesicles. F-exo and F-exo CT were isolated by ultracentrifugation of the 10 K
supernatant at 100,000× g (100 K) for 3 h, and the resulting pellet washed in PBS for 3 h at 100,000× g.
All ultracentrifugation steps were performed at 4 ◦C using a SW41 Ti rotor (Beckman Coulter, Brea, CA,
USA). The final pellet was resuspended in PBS and quantified by FACS (FC Gallios Flow Cytometer
and Kaluza Software-Beckman Coulter). To set the instrument, fluorescent beads (525/540 nm FL1)
ranging in size from 0.1 to 0.5 µm were analyzed. Flow count fluorospheres, used to determine
exosome number, were resuspended in PBS with F-exo and F-exo CT, and the instrument was set to
fix the stopping gate on 2000 flow count fluorospheres. For further details, refer to [15]. For F-exo
biogenesis studies, F-exo CT were collected at different time points (1–24 h) after 2 h of CT incubation.
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4.6. Iodixanol/OptiPrepTM Gradient Separation
A discontinuous iodixanol gradient was used for further exosome purification, as described by
several authors [41]. Solutions of 10%, 30% and 40% iodixanol were made up by mixing appropriate
amounts of homogenization buffer (HM solution: 0.25 M sucrose, 1 mM EDTA, 10 mM Tris-HCL
pH = 7.4) and an iodixanol working solution. This working solution was prepared by combining
a working solution buffer (0.25 M sucrose, 6 mM EDTA, 60 mM Tris-HCL pH = 7.4) and a stock
solution of OptiPrepTM (60% w/v aqueous iodixanol solution, Sigma-Aldrich, Saint Louis, MS, USA).
The gradient was formed by layering 1 mL of 60% with 0.260 mL sample, 0.5 mL 40%, 0.5 mL 30%
and 1.8 mL of 10% solutions on top in a 4.5 mL open top polyallomer tube (Beckman Coulter, Brea,
CA, USA). The gradient was then centrifuged for 18 h at 192,000× g at 4 ◦C (SW60 Ti rotor Beckman
Coulter). Gradient fractions of 350 µL were collected from the top of the gradient and analyzed by
FACS for exosome count. Fractions were loaded on a SDS-PAGE gel for Western blotting analysis using
antibodies directed against exosome markers TSG101 and Alix. For CT detection, gradient fractions
were TCA precipitated. The refractive index of each fraction was assessed with a refractometer (Carl
Zeiss, Oberkochen, Germany), and the relative density was calculated using the linear relationship
between refractive index (η) and the density (ρ) ρ = Aη − B.
4.7. Chymotrypsin Treatment of exo
To analyze the intra/extra localization of CT, exo CT (16 µg) were incubated with or without 1 µg
of chymotrypsin, in the absence or presence of 0.2% Triton X-100, at 37 ◦C for 3 h at pH 7.8. Digestion
was stopped on ice with 5 µM phenylmethanesulfonyl fluoride (PMSF). Samples were then mixed
with Laemmli buffer, heated at 95 ◦C for 5 min, and analyzed by SDS-PAGE and western blotting.
4.8. cAMP Assay
Freshly trypsinized cells were transferred to 6-well plates (2 × 105 cells/well) and incubated
overnight at 37 ◦C in DMEM with 10% FBS to allow cell attachment. Plates were then washed with
serum-free DMEM, and 1 mL of 1% FBS DMEM containing 0.5 mM 1-methyl-3-isobutylxantine (IBMX,
Sigma-Aldrich, Saint Louis, MO, USA) was added for 30 min. As control, IBMX treated cells were
used. After incubation, 0.2 ng/mL of CT or a specific number (5.7 × 107) of F-exo and F-exo CT were
added and plates were incubated at 37 ◦C for 4 h. Cells were washed in ice-cold PBS, and cAMP assay
was performed, according to manufacturer’s instructions (Cyclic AMP XP Assay kit, Cell Signaling
Technology, Danvers, MA, USA).
4.9. Confocal Microscopy
To analyze the intracellular localization of CT, Me665cells (4 × 104) were cultured on 24-well
plates containing coverslips until 60–70% of confluency. Cells were incubated at 37 ◦C with or
without 7 µM BODIPY C16 for 4 h. 12 nM CT was added for 20 min on ice (T0), and cells were then
incubated at 37 ◦C for 24 h (T24). Cells were fixed with 3 % paraformaldehyde (PFA) for 20 min at
RT and permeabilized with 0.05% saponin. The primary antibodies used were: rabbit polyclonal
anti-Cholera toxin (Sigma-Aldrich), mouse anti-TSG101 (GeneTex, Hsinchu, Taiwan), and mouse
anti-LBPA/BMP (6C4) (Echelon Corporation, San Jose, CA, USA). AlexaFluor647-conjugated and
AlexaFluor488-conjugated goat anti mouse or anti rabbit (Life Technologies) was used as secondary
antibody. Coverslips were mounted on the microscope slide with Vectashield antifade mounting
medium containing DAPI (Vector Laboratories, Burlingame, CA, USA). Images were taken by a FV1000
confocal microscope (Olympus, Tokyo, Japan), using a (Olympus) planapo objective 60x oil A.N. 1.42.
Excitation light was obtained by a Laser Dapi 408 nm for DAPI, an Argon Ion Laser (488 nm) for FITC
(Alexa 488), and a Red Diode Laser (638 nm) for Alexa 647. DAPI emission was recorded from 415 to
485 nm, FITC emission was recorded from 495 to 550 nm, and Alexa 647 from 634 to 750 nm. Images
recorded have an optical thickness of 0.3 mm.
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4.10. F-exo and F-exo CT Transfer
To evaluate the transfer on target cells, F-exo were incubated with cells in a 24-well plate in
duplicate in 1 mL DMEM with 0.1% FBS and kept for 4 h at 37 ◦C in CO2 incubator. The medium was
then removed, and cells PBS washed, detached and subjected to FACS analysis for cell fluorescence,
together with exo and a standard curve setup with Quantum™ FITC-5 MESF (Molecules of Equivalent
Soluble Fluorophores) (Bangs Laboratories, Inc., Fishers, IN, USA). The amount of transferred exo was
estimated, as previously described [15]. Briefly, we transformed fluorescence data (arithmetic mean)
of exo using the QuickCal analysis template provided with each Quantum™ MESF lot to determine
MESF per Exo and cells. To transform MESF associated to cells in number of Exo transferred, we used
the formula: transferred Exo number = (cell fluorescence (MESF) − autofluorescence (MESF))/MESF
associated to a single Exo. For confocal microscopy, 4 × 104 cells were seeded on a sterilized coverslip
and incubated with 2 × 108 F-exo, or F-exo CT for 4 h at 37 ◦C in DMEM with 0.1% FBS. At the end of
incubation, the medium was removed, and the cells were washed with PBS and fixed with 3% PFA
for analysis.
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